Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab
- Sponsor
- Dongyang People's Hospital
- Study ID
- NCT06234514
- Phase
- PHASE4
- Status
- Completed
Conditions
- Macular Cystoid Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Jueling Mingmu decoction — DRUGJueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
- intravitreal injections of 0.5mg ranibizumab — DRUGPatients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
Study Details
The objective of this study was to investigate the efficacy and safety of traditional Chinese medicine (Jueling Mingmu Decoction) combined with ranibizumab in the treatment of macular edema with retinal vein obstructive.
Key Dates
- First listed
- Jan 31, 2024
- Start date
- Jan 1, 2023
- Status verified
- Aug 2025
- Primary completion
- May 31, 2025
- Completion
- May 31, 2025
Study Design
- Enrollment
- 111 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Combination Therapy GroupDuring the initial month, the patient consumed Jueling Mingmu decoction daily for one month. Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
- Active Comparator: Intravitreal Ranibizumab GroupPatients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
Primary Outcome Measure
Mean number of injections [ Time Frame: 48 weeks ]